Physician profile
Jonathan Burt
NPI 1447608807
$2,438.63
in general payments reported to CMS, 2019-2025
13 companies · $217 in 2025
The $217 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $131 · 2021: $343 · 2022: $510 · 2023: $446 · 2024: $482 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,144.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $686.94 | 2019-2024 | Acuvue |
| Coopervision INC. | $463.90 | 2019-2025 | Myday Contact Lens, Misight Contact Lens |
| Alcon Vision LLC | $288.82 | 2019-2025 | Tryptyr, Simbrinza |
| Sun Pharmaceutical Industries INC. | $188.51 | 2022-2024 | Cequa |
| Lombart Brothers, INC. | $172.56 | 2019 | |
| Dompe US, INC. | $165.18 | 2024 | Oxervate |
| Oyster Point Pharma, INC. | $145.52 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $140.48 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $78.00 | 2024-2025 | Infuse |
| Novartis Pharmaceuticals Corporation | $44.63 | 2022 | |
| Shire North American Group INC | $26.33 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $22.26 | 2024 | |
| Biotissue Holdings INC. | $15.50 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Burt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.